Regulation of University Biotechnology Commercialization in China

1. Introduction

University biotechnology commercialization in China refers to the legal process through which universities, research institutes, professors, and scientific researchers transform biotechnology discoveries into commercially valuable products, including gene therapies, vaccines, diagnostic tools, genetically modified organisms, microbial technologies, and pharmaceutical innovations.

China regulates this process through a combination of intellectual property law, technology-transfer legislation, university research-management rules, biosafety requirements, pharmaceutical regulations, and laws governing state-owned assets. The central challenge is to encourage innovation while protecting public investment, scientific integrity, human health, and national security.

The principal legal framework includes the Patent Law of the People's Republic of China, the Law on Promoting the Transformation of Scientific and Technological Achievements, the Civil Code, the Biosecurity Law, the Biosafety Law-related implementing measures, and the regulations governing human genetic resources and drug registration.

2. Principal Legal Framework

A. Law on Promoting the Transformation of Scientific and Technological Achievements

This law, adopted in 1996 and substantially amended in 2015, is the foundation of university technology commercialization in China.

It encourages universities and research institutions to transfer scientific achievements to enterprises through licensing, assignment, investment, and other forms of technology transfer.

Its principal features include:

Universities may commercialize eligible scientific and technological achievements generated through their research activities.

Research institutions receive greater autonomy in deciding how to transfer eligible achievements, subject to applicable public-asset, financial, and institutional requirements.

Researchers may receive rewards or remuneration from the commercialization of their achievements.

Technology transfer can take place through licensing, assignment, cooperation with enterprises, or investment using intellectual property.

The law seeks to reduce bureaucratic barriers that historically discouraged universities from commercializing publicly funded discoveries.

However, commercialization rights are not unlimited. The ownership of the invention, the source of funding, employment agreements, institutional rules, and any restrictions attached to public funding must be examined before a transaction is completed.

B. Patent Law of China

China's Patent Law protects eligible biotechnology inventions, including certain genetic engineering methods, microorganisms, diagnostic technologies, pharmaceutical compositions, and industrial biotechnology processes.

Patent protection is particularly important when a university licenses a biotechnology invention to a pharmaceutical company or establishes a spin-off enterprise.

A university must distinguish between:

Patentable technical inventions.

Biological materials and naturally occurring substances, which may face different eligibility rules.

Research data, confidential know-how, and manufacturing processes protected through contractual or trade-secret mechanisms.

Research results that are already publicly disclosed and may no longer satisfy novelty requirements.

The patent application must meet statutory requirements for patentability, disclosure, and inventorship. For biotechnology, adequate disclosure and reproducibility may be particularly significant where biological materials are difficult to describe solely in written terms.

C. Civil Code and Technology Transfer Contracts

The Civil Code, effective from 2021, provides general rules governing contracts, intellectual property-related transactions, liability, and the protection of legitimate interests.

University biotechnology agreements commonly address:

Ownership of background and newly developed intellectual property.

Licensing scope, exclusivity, and territorial rights.

Milestone payments, royalties, and sublicensing.

Confidentiality and publication restrictions.

Allocation of regulatory and product-development responsibilities.

Liability for infringement, product defects, and contractual breaches.

A university should not assume that transferring patent rights automatically transfers ownership of biological samples, research data, regulatory dossiers, or third-party intellectual property. These assets may require separate legal analysis and contractual provisions.

D. Biosecurity Law and Biotechnology Regulation

China's Biosecurity Law establishes a framework for controlling biotechnology activities that may affect public health, ecological security, or national security. Universities commercializing engineered microorganisms, gene-editing technologies, or other potentially hazardous biological products must assess whether the relevant research and development activities trigger biosafety requirements.

Where commercialization involves human genetic resources, the Regulations on the Administration of Human Genetic Resources, as amended in 2024, are particularly important. They regulate the collection, preservation, use, and external provision of Chinese human genetic resources. International research collaborations may require approval, filing, or security review, depending on the activity.

Moj

+1

3. Ownership and Commercialization of University Inventions

Under China's technology-transfer framework, an invention created by a researcher in the course of assigned university duties, or substantially using the university's material and technical resources, may qualify as a service invention or job-related scientific achievement.

The university's ownership rights must be distinguished from the researcher's entitlement to rewards. Article 18 of the Law on Promoting the Transformation of Scientific and Technological Achievements permits eligible state-maintained research institutions and universities to decide independently on transfers, licences, and investments involving achievements they hold, subject to applicable procedures.

Universities may commercialize biotechnology through:

Exclusive or non-exclusive patent licensing.

Assignment of patents and associated technology.

Establishment of university spin-off companies.

Equity investment using eligible intellectual property.

Collaborative research and development agreements.

For negotiated transactions, the law provides for disclosure of the proposed transaction and price within the institution. Article 19 also supports arrangements under which researchers participate in commercialization while ownership remains unchanged. The precise financial entitlement depends on applicable law, institutional policies, and agreements.

UNITALEN ATTORNEYS AT LAW

+1

4. Relevant Case Law

Case 1: Wanfu Biotechnology and Yuyue Medical Patent Ownership Dispute

Case: Supreme People's Court Intellectual Property Court, (2019) Zui Gao Fa Zhi Min Zhong No. 799, decided in 2021.

The dispute concerned ownership of a patent application relating to a blood-gas analyser and its testing card. The Supreme People's Court explained that an invention made within one year after an employee leaves an employer may still constitute a service invention if it relates to the former employer's work or assigned tasks. Patent application rights may therefore belong to the former employer, even if the invention also relates to the new employer's activities.

最高人民法院知识产权法庭

Legal significance: Although this was not a university biotechnology commercialization case, its reasoning is relevant when university researchers leave to establish biotechnology companies. A spin-off cannot safely assume that inventions developed by a newly recruited professor belong to the company merely because they were developed after recruitment. Research assignments, invention records, laboratory access, and the timing of development should be documented carefully.

Case 2: He Jiankui Genome-Editing Criminal Case

In 2019, a Chinese court convicted He Jiankui and two collaborators for illegally conducting human embryo gene-editing activities. The court imposed prison sentences and fines. The case is relevant to the commercialization of reproductive biotechnology because it demonstrates that commercial or entrepreneurial objectives do not displace mandatory research, medical, and ethical safeguards.

Legal significance: The case should not be treated as a patent ownership precedent or a direct university technology-transfer dispute. Rather, it illustrates the limits of commercialization where biotechnology research violates applicable medical and ethical requirements.

Note: These examples do not establish that China has a comprehensive body of reported judicial decisions specifically addressing university biotechnology commercialization. The statutory framework and related patent disputes remain central to evaluating most transactions.

5. Regulatory Risks and Practical Compliance

A university intending to commercialize a gene therapy, engineered microorganism, vaccine, or diagnostic platform should undertake the following steps:

Establish ownership of patents, biological materials, data, and confidential know-how.

Review grant conditions, employment agreements, and university technology-transfer policies.

Document valuation, institutional disclosures, researcher remuneration, and transaction approval.

Obtain relevant biosafety, ethics, clinical-trial, and product-registration authorizations.

Review human genetic resources obligations and cross-border data restrictions where applicable.

Define intellectual property ownership, publication rights, royalties, indemnities, and regulatory responsibilities in writing.

6. Conclusion

China's approach combines commercialization incentives with institutional ownership, researcher reward mechanisms, intellectual property protection, and strict oversight of sensitive biotechnology. The 2015 reform of the technology-transfer law strengthened universities' autonomy, while biosafety and human genetic resources rules impose additional conditions on high-risk and internationally collaborative projects.

The key legal principle is that permission to commercialize a university invention does not automatically authorize every subsequent research, clinical, manufacturing, or cross-border activity. Each stage must satisfy its own legal requirements.